PBT2   Click here for help

GtoPdb Ligand ID: 11108

Synonyms: PBT-1033 | PBT-2 | PBT1033
Compound class: Synthetic organic
Comment: PBT2 is an orally administered, safe-in-humans zinc ionophore. Chemically it is an 8-hydroxyquinoline analogue. PBT2 has been classified as a metal-protein attenuating compound (MPAC), and is designed to interfere with zinc ion interactions with proteins.
Antibacterial activity: Whilst not active alone, PBT2 + zinc + antibacterial 'X' acts synergistically to overcome acquired bacterial-resistance to antibacterial 'X' (which can include clinically used antibacterials). This strategy produces activity against antibacterial-resistant Gram-positive pathogens [1].
SARS-CoV-2: Based on evidence from previous studies in MERS-CoV and SARS-CoV-1, zinc modulation (e.g. by PBT2 or disulfiram [4]) has been proposed as a potential mechanism for the prophylaxis/treatment of COVID-19. Altering zinc ion levels is predicted to affect activity of host and/or viral zinc-containing metalloenzymes.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 36.36
Molecular weight 270.03
XLogP 2.8
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN(Cc1ccc2c(n1)c(O)c(cc2Cl)Cl)C
Isomeric SMILES CN(Cc1ccc2c(n1)c(O)c(cc2Cl)Cl)C
InChI InChI=1S/C12H12Cl2N2O/c1-16(2)6-7-3-4-8-9(13)5-10(14)12(17)11(8)15-7/h3-5,17H,6H2,1-2H3
InChI Key YZPOQCQXOSEMAZ-UHFFFAOYSA-N
References
1. Bohlmann L, De Oliveira DMP, El-Deeb IM, Brazel EB, Harbison-Price N, Ong CY, Rivera-Hernandez T, Ferguson SA, Cork AJ, Phan MD et al.. (2018)
Chemical Synergy between Ionophore PBT2 and Zinc Reverses Antibiotic Resistance.
mBio, 9 (6). DOI: 10.1128/mBio.02391-18 [PMID:30538186]
2. Huntington Study Group Reach2HD Investigators. (2015)
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
Lancet Neurol, 14 (1): 39-47. [PMID:25467848]
3. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R et al.. (2008)
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
Lancet Neurol, 7 (9): 779-86. [PMID:18672400]
4. Lin MH, Moses DC, Hsieh CH, Cheng SC, Chen YH, Sun CY, Chou CY. (2018)
Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes.
Antiviral Res, 150: 155-163. [PMID:29289665]